

**Government of the District of Columbia  
Department of Health**

**Prescription Drug Monitoring Program  
Advisory Committee Meeting**

**899 NORTH CAPITOL ST. NE – 2<sup>ND</sup> FLR.  
WASHINGTON, DC 20002**

**April 30, 2019**

**10:00am- 12:00 pm**

**OPEN SESSION AGENDA**



## Open Session Agenda

<b>Introduction:</b>		
<b>0430-O-01</b>	<p><b><u>Welcome &amp; Introductions</u></b></p> <p><b><u>Charge of the Committee</u></b></p> <p>The Committee shall convene at least two (2) times per year to advise the Director:</p> <ul style="list-style-type: none"><li>(a) On the implementation and evaluation of the Program;</li><li>(b) On the establishment of criteria for indicators of possible misuse or abuse of covered substances;</li><li>(c) On standardization of the methodology that should be used for analysis and interpretation of prescription monitoring data;</li><li>(d) In determining the most efficient and effective manner in which to disclose the findings to proactively inform prescribers regarding the indications of possible abuse or misuse of covered substances;</li><li>(e) On identifying drugs of concern that demonstrate a potential for abuse and that should be monitored; and</li><li>(f) Regarding the design and implementation of educational courses for:<ul style="list-style-type: none"><li>(1) Persons who are authorized to access the prescription monitoring information;</li><li>(2) Persons who are authorized to access the prescription monitoring information, but who have violated the laws or breached professional standards involving the prescribing, dispensing, or use of any controlled substances or drugs monitored by the Program;</li><li>(3) Prescribers on prescribing practices, pharmacology, and identifying, treating, and referring patients addicted to or abusing controlled substances or drugs monitored by the Program; and</li><li>(4) The public about the use, diversion and abuse of, addiction to, and treatment for the addiction to controlled substances or drugs monitored by the Program.</li></ul></li></ul>	
<b>0430-O-02</b>	<p><b><u>Approval of January 2019 PDMP Advisory Committee Meeting Minutes</u></b></p> <ul style="list-style-type: none"><li>(a) Minutes from January 15, 2019 Meeting</li></ul>	

<b>0430-O-03</b>	<b><u>2018 PDMP Advisory Committee Year in Review</u></b>	
<b>0430-O-04</b>	<b><u>Report from Attorney Advisor</u></b> (a) PDMP Legislative Update (b) Update: Gabapentin to be added as drug of concern	
<b>0430-O-05</b>	<b><u>Program Updates</u></b> (a) Program Statistics (b) Past and Future Outreach Activities (c) PDMP Best Practice Checklist updates and discussion	
<b>0430-O-06</b>	<b><u>Grant Updates</u></b> (a) Statewide Gateway Integration (b) Professional License Integration (c) Opioid Indicator Dashboard (d) Opioid Awareness Communications Campaign	
<b>0430-O-07</b>	<b><u>PDMP Annual Report</u></b>	
<b>0430-O-08 Matters for Consideration</b>	<b><u>Action Items</u></b> <ul style="list-style-type: none"> <li>• Future meeting dates: <ul style="list-style-type: none"> <li>- July 16th, 2019</li> <li>- October 15th, 2019</li> </ul> </li> </ul>	
<b>0430-O-09</b>	<ul style="list-style-type: none"> <li>• Other news/highlights from Committee members</li> </ul>	
<b>Comments from the Public</b>		
<b>Motion to Adjourn the Open Session</b>	Madam Chair, I move that the Committee close the Open Public session portion of the meeting.  (Roll Call Vote)	

This concludes the Public Open Session of the meeting.

**Open Session Meeting Adjourned at \_\_: \_\_ PM**